Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events - HPS2-THRIVE

Description:

The goal of the trial was to evaluate treatment with extended-release niacin/laropiprant compared with placebo among high-risk patients treated with statin therapy. Laropiprant is a prostaglandin D2 receptor antagonist, which reduces niacin-associated flushing.